Key Proteo Raises $2.3M Series A for Proteomics-Based Newborn Screening

Key Proteo, a Seattle-based proteomics diagnostics company, has raised a $2.3 million Series A round. The funding was dated October 23, 2026. No lead investor or additional participating investors were disclosed with the round.

What the Company Does

Founded in 2019, Key Proteo develops early detection of rare but treatable genetic disorders, beginning with newborn screening. Its patent-pending Immuno-SRM platform quantifies extremely low-abundance protein biomarkers from a few drops of blood. According to the company, the platform offers faster turnaround and lower cost than next-generation sequencing.

Product and Clinical Progress

The company's first panel targets four disorders, including Wilson disease and Wiskott-Aldrich syndrome. Key Proteo earned CLIA certification in 2025, and Wilson disease screening was added to the Washington State newborn screening program that year.

Why It Matters for Acquirers

Key Proteo sits at the intersection of two areas that have drawn sustained strategic interest: newborn screening infrastructure and protein-level diagnostics that can complement or displace sequencing-based workflows. The company's value proposition rests on three elements:

• Sample efficiency: quantification of low-abundance biomarkers from a few drops of blood, a practical requirement for newborn screening settings.
• Turnaround and cost: positioning against next-generation sequencing on speed and economics.
• Regulatory and reimbursement footing: CLIA certification in 2025 and inclusion of Wilson disease screening in Washington State's newborn screening program.

For strategic buyers in diagnostics, laboratory services, or rare disease therapeutics, Key Proteo offers a platform with an initial commercial pathway in newborn screening and a panel that could expand beyond its first four targets. The Series A is modest in size, which may reflect an early-stage capital need tied to panel expansion and laboratory operations rather than a large-scale commercial build-out.

Round Details

• Company: Key Proteo
• Headquarters: Seattle
• Founded: 2019
• Round type: Series A
• Amount: $2.3 million
• Currency: USD
• Date: October 23, 2026
• Lead investor: Not disclosed
• Other investors: Not disclosed

What to Watch

Key Proteo's next milestones will likely center on broadening its panel beyond the initial four disorders, deepening payer and public health program coverage following the Washington State addition, and demonstrating that the Immuno-SRM platform scales across additional low-abundance protein biomarkers. Each of these would materially affect the company's strategic value to a potential acquirer.